ArticleThe Lancet regional health. Southeast Asia2023

Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study.

Winsley Rose et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.